The University of Texas MD Anderson Cancer Center and BostonGene Corporation today announced a strategic alliance to advance the development and clinical integration of multiplatform biomarker signatures. The alliance brings together BostonGene’s innovative computational platform and CLIA-certified and CAP-accredited high complexity molecular laboratory with the clinical and translational research expertise of MD Anderson, leveraging scientific discovery, analytical advancement and powerful computing to develop clinically applicable solutions for patients with cancer. BostonGene’s computational platform evaluates myriad molecular and immune-based parameters […]
